TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00801905

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nepafenac
Description: Topical nepafenac 0.1% is administrated every 6 hour 1 week before start pan-retinal photocoagulation and 4 weeks during all laser session performed biweekly, and 4 weeks after last laser sessión was completed.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lubricant
Description: Topical lubricating is administrated every 6 hours at fellow eye 1 week before start pan-retinal photocoagulation, 4 weeks during each laser session performed biweekly, and 4 weeks after last laser sessión was completed
Study: NCT00482625

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT03059056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25mg
Description: Samples from six, healthy, adult, male, smoking, Egyptian volunteers (age: 22-33 years, Average weight: 77.8 kg, Average BMI: 29.2) will be collected at 0, 0.5, 1, 1.5, 2, 3, 4, 8 and 12 h after administration of Empagliflozin 25 mg
Study: NCT04061772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmorubicin
Description: Pharmorubicin injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone tablet
Study: NCT01469819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Description: 24 mcg twice a day (BID) for 2 weeks.
Study: NCT02721849

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga for adolescents
Description: 12 week hatha yoga course for adolescents

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga for adolescents
Description: 12 week hatha yoga course for adolescents

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga for parents
Description: 12 week hatha yoga course

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga for parents
Description: 12 week hatha yoga course
Study: NCT01249378

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: All subjects receive three sequences of a standard breakfast
Description: All subjects receive three sequences of a standard breakfast containing :~* 10 g non emulsified~* or 40 g non emulsified~* or 40 g finely emulsified of milk fat with stable isotope (13C triglyceride). The administration order is determined by randomized allocation. The wash-out period is three weeks. There are not diet or exercise interventions. Only, one week before and three days after, the subjects consume neither naturally enriched in 13C foods or pre/probiotics. In addition, three days before and three days after each test, the subjects receive dietary instructions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: All subjects receive three sequences of a standard breakfast
Description: All subjects receive three sequences of a standard breakfast containing :~* 10 g non emulsified~* or 40 g non emulsified~* or 40 g finely emulsified of milk fat with stable isotope (13C triglyceride). The administration order is determined by randomized allocation. The wash-out period is three weeks. There are not diet or exercise interventions. Only, one week before and three days after, the subjects consume neither naturally enriched in 13C foods or pre/probiotics. In addition, three days before and three days after each test, the subjects receive dietary instructions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: All subjects receive three sequences of a standard breakfast
Description: All subjects receive three sequences of a standard breakfast containing :~* 10 g non emulsified~* or 40 g non emulsified~* or 40 g finely emulsified of milk fat with stable isotope (13C triglyceride). The administration order is determined by randomized allocation. The wash-out period is three weeks. There are not diet or exercise interventions. Only, one week before and three days after, the subjects consume neither naturally enriched in 13C foods or pre/probiotics. In addition, three days before and three days after each test, the subjects receive dietary instructions
Study: NCT03917342

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EEG measure
Description: Frontal 3-derivation EEG measure under different conditions in pregnancy (healthy vs preeclampsia) and baseline non-pregnant women

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EEG measure
Description: Frontal 3-derivation EEG measure under different conditions in pregnancy (healthy vs preeclampsia) and baseline non-pregnant women

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EEG measure
Description: Frontal 3-derivation EEG measure under different conditions in pregnancy (healthy vs preeclampsia) and baseline non-pregnant women
Study: NCT00992030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: I.V. infusion weekly x 6 weeks at a dose of 375 mg/m2

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Involved field irradiation
Description: Radiation therapy, limited to initially involved nodal sites, will start within four weeks from the last cycle of ABVD chemotherapy and after complete restaging with TAC total-body and PET total-body. The planned total dose is 30,6 Gy.
Study: NCT02105688

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet (MK-5172A)
Description: Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet, taken once daily by mouth for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet (MK-5172A)
Description: Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet, taken once daily by mouth for 12 weeks.
Study: NCT02001987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate will be administered at a stable dose that was initiated at least 4 weeks prior to Baseline, at investigator's discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: csDMARDs
Description: csDMARDs (at investigator's discretion) will be administered at a stable dose that was initiated at least 4 weeks prior to Baseline, at investigator's discretion.
Study: NCT02818101

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis session
Study: NCT02105688

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet
Description: Placebo Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet, taken once daily by mouth for 12 weeks.
Study: NCT01762345

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pessary (disposable intra-vaginal device)
Description: pessary device(disposable intra-vaginal device)manufactured by Procter \& Gamble
Study: NCT03114592

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth tool
Description: The curriculum in the mHealth tool was derived in consultation with patient safety, informatics and adult educational curricula experts, and is comprised of clinical vignettes describing the post-hospital discharge stories of two hypothetical AKI survivors. opics of emphasis included NSAID risk awareness and avoidance of volume depletion when ill (Sick Day Protocol).
Study: NCT00482625

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01066728

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CO2 inhalation
Description: Inhalation of CO2 (3% at the source, approximately 1% inhaled) with room air by nasal prongs at 0.5 l/min for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Theophylline
Study: NCT01186991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onartuzumab
Description: Onartuzumab will be administered as intravenous (IV) infusion at a dose of 10 milligrams per kilogram (mg/kg) on Day 1 and Day 15 of each 28-day cycle. The dose of onartuzumab will be based on the participant's weight at screening and will remain the same throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onartuzumab
Description: Onartuzumab will be administered as intravenous (IV) infusion at a dose of 10 milligrams per kilogram (mg/kg) on Day 1 and Day 15 of each 28-day cycle. The dose of onartuzumab will be based on the participant's weight at screening and will remain the same throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered as IV infusion at a dose of 10 mg/kg on Day 1 and Day 15 of each 28-day cycle. The dose of bevacizumab will be based on the participant's weight at screening and will remain the same throughout the study.
Study: NCT02831088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neu2000KWL High-does group
Description: 1st infusion of 750mg in patients receiving endovascular therapy within 8 hours following ischemic stroke onset followed by 9 consecutive infusions of 500 mg at intervals of 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neu2000KWL Low-does group
Description: 1st infusion of 500mg in patients receiving endovascular therapy within 8 hours following ischemic stroke onset followed by 9 consecutive infusions of 250 mg at intervals of 12 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1st infusion of the same volume of saline in patients receiving endovascular therapy within 8 hours following ischemic stroke onset followed by 9 consecutive infusions of same volume of saline at intervals of 12 hours
Study: NCT01186991

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab will be administered as IV infusion at a dose of 10 mg/kg on Day 1 and Day 15 of each 28-day cycle. The dose of bevacizumab will be based on the participant's weight at screening and will remain the same throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered as IV infusion at a dose of 90 milligrams per meter-squared (mg/m\^2) on Day 1, Day 8, and Day 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered as IV infusion at a dose of 90 milligrams per meter-squared (mg/m\^2) on Day 1, Day 8, and Day 15 of each 28-day cycle.
Study: NCT02938819

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard upper limb intervention
Description: The standard upper limb intervention involved active upper limb range of motion, manual dexterity involving grasp and manipulation of small pieces such as marbles and stretching upper limb exercises.
Study: NCT01642862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Comparison of pharmacokinetic parameters of different formulations (liquid vs tablet) and doses (20 or 40 mg) of simvastatin after single oral administration of the drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Comparison of pharmacokinetic parameters of different formulations (liquid vs tablet) and doses (20 or 40 mg) of simvastatin after single oral administration of the drug
Study: NCT00359866

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT with tomotherapy
Study: NCT00887562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idebenone
Description: 900 mg/day for 1 month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idebenone
Description: 2250 mg/day for 1 month

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - No idebenone
Study: NCT04227730

Intervention type: DIAGNOSTIC_TEST
Intervention: culture and PCR for group B streptococcus
Description: all participants were evaluated by vaginorectal specimens for the detection of GBS, The swabs are placed in Amies transport medium and sent to the microbiology laboratory for testing by conventional PCR assay.

Intervention type: DIAGNOSTIC_TEST
Intervention: culture and PCR for group B streptococcus
Description: all participants were evaluated by vaginorectal specimens for the detection of GBS, The swabs are placed in Amies transport medium and sent to the microbiology laboratory for testing by conventional PCR assay.
Study: NCT00681434

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: bilateral upper extremity training
Description: Bilateral symmetrical upper extremity training for proximal control for three hours per week for eight weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unilateral upper extremity training
Description: Unilateral upper extremity training for proximal extremity for three hours a week for eight weeks.
Study: NCT01186991

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel will be administered as IV infusion at a dose of 90 milligrams per meter-squared (mg/m\^2) on Day 1, Day 8, and Day 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Placebo
Description: Placebo matching to bevacizumab will be administered as IV infusion on Day 1 and Day 15 of each 28-day cycle.
Study: NCT02122874

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Neurostimulation (PENS) of dermatome T7
Description: The patients undergo PENS of dermatome T7 and follow a 1200 Kcal diet

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Neurostimulation (PENS) of dermatome T7
Description: The patients undergo PENS of dermatome T7 and follow a 1200 Kcal diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1200 Kcal diet
Study: NCT02319317

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risky driving prevention
Description: The web-based intervention to prevent risky driving targets knowledge, attitudes, perceived control and norms about driver inattention, with strategies to keep attention on the roadway.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control group general health promotion
Description: The control group will receive a web-based intervention for general health promotion and is designed to enhance participants' knowledge and ability to reduce their risk of adverse health conditions including, obesity and heart disease.
Study: NCT01530464

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminophylline
Description: Drug will be administered as a single oral dose of 500mg, followed by a 48h washout period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ambrisentan
Description: Drug will be administered as a single dose of 5mg, followed by a 48h washout period
Study: NCT00692198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen therapy
Description: Oxygen dose at rest and during sleep will be 2 L/min via nasal cannula. The oxygen dose used while walking will be individually prescribed and will be sufficient to maintain oxygen saturation at 90% or above for at least 2 minutes while walking. Participants who have low blood oxygen levels at rest will be instructed to use oxygen 24 hours per day. Participants who have normal resting blood oxygen levels, but low or very low blood oxygen levels during exercise, will be instructed to use oxygen during physical activity and sleep.
Study: NCT01795534

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot shot then placebo shot
Description: Beetroot shot, four day wash out, then placebo shot

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo shot then beetroot shot
Description: Placebo shot, four day wash out, then beetroot shot
Study: NCT01737203

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Viagra
Description: 50 mg tablet on Day 1 of each period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil ODT
Description: 50 mg tablet on Day 1 of each period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil ODT
Description: 50 mg tablet on Day 1 of each period
Study: NCT04392791

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: balneotherapy
Description: Balneotherapy, a medical remedy, with medically and legally recognized mineral waters for therapeutic and rehabilitation purposes
Study: NCT04647175

Intervention type: OTHER
Group type: OTHER
Intervention: Fermented aronia
Description: Given twice daily for 8 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Fermented aronia
Description: Given twice daily for 8 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Fermented aronia
Description: Given twice daily for 8 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Fermented aronia
Description: Given twice daily for 8 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Fermented aronia
Description: Given twice daily for 8 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Fermented aronia
Description: Given twice daily for 8 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Aronia
Description: Given twice daily for 8 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Aronia
Description: Given twice daily for 8 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Aronia
Description: Given twice daily for 8 weeks
Study: NCT01186991

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Onartuzumab Placebo
Description: Placebo matching to onartuzumab will be administered as IV infusion on Day 1 and Day 15 of each 28-day cycle.
Study: NCT03828617

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20vPnC
Description: 20vPnC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20vPnC
Description: 20vPnC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20vPnC
Description: 20vPnC

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13vPnC
Description: Pneumococcal conjugate vaccine
Study: NCT04616859

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alcohol and Energy Drink (AmED)
Description: Multiple oral dose of alcohol mixed with ED

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol and Energy drink Placebo
Description: Multiple oral dose of alcohol mixed with ED placebo (soft drink)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol placebo and Energy drink
Description: Multiple oral dose of alcohol placebo (water) mixed with ED

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Alcohol placebo and energy drink placebo
Description: Multiple oral dose of alcohol placebo (water) mixed with ED placebo (soft drink)
Study: NCT04338308

Intervention type: DEVICE
Intervention: new-DES
Description: with ot without embolic protection device

Intervention type: DEVICE
Intervention: BMS
Description: with ot without embolic protection device
Study: NCT01512095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: A single dose administered subcutaneously (under the skin) on 2 separate dosing visits (treatment periods) separated by a wash-out period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: somatropin
Description: A single dose administered subcutaneously (under the skin) on 2 separate dosing visits (treatment periods) separated by a wash-out period
Study: NCT02259465

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: low FODMAP diet
Description: Participants will attend a one-hour group session on how to follow the low FODMAP diet, run by a dietitian trained in the diet. They will be asked to follow the diet for 7 days while keeping a food diary.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: low FODMAP diet
Description: Participants will attend a one-hour group session on how to follow the low FODMAP diet, run by a dietitian trained in the diet. They will be asked to follow the diet for 7 days while keeping a food diary.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oligofructose
Description: Participants will supplement their diet with 7 grams of OF twice daily for the week that they follow the low FODMAP diet.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Participants will supplement their diet with 7 grams of maltodextrin twice daily for the week that they follow the low FODMAP diet.
Study: NCT01530464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminophylline plus ambrisentan
Description: Drugs will be given as single doses of 500mg (aminophylline) and 5mg (ambrisentan), followed by a 48h washout period